All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Steven Treon from Dana-Farber Cancer Institute, Boston, US, about the long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib.
Steven Treon discusses the long-term follow-up of a multi-institutional trial investigating ibrutinib, which is highly active in patients with Waldenstrom's macroglobulinemia.
Long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib
ICML 2019 | Which patients with MCL could benefit most from ibrutinib plus rituximab in the front-line setting?
During ICML 2019 in Lugano, the Lymphoma Hub were pleased to speak to Preetesh Jain from MD Anderson Cancer Center, Houston, US, about...
ICML 2019 | Overview of the phase II SMART START trial
The Lymphoma Hub were pleased to speak to Dr. Jason Westin, MD Anderson Cancer Center, Texas, US about the phase II SMART SMART trial of rituximab, lenalidomide, and ibrutinib alone prior to...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox